Cargando…
Role of ILC2s in Solid Tumors: Facilitate or Inhibit?
Group 2 innate lymphoid cells (ILC2s) are important mediators of type 2 immunity and play an important role in allergic diseases, helminth infections, and tissue fibrosis. However, the role of ILC2s in tumor immunity requires further elucidation. Studies over the past decade have reported that ILC2s...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203687/ https://www.ncbi.nlm.nih.gov/pubmed/35720302 http://dx.doi.org/10.3389/fimmu.2022.886045 |
_version_ | 1784728751237496832 |
---|---|
author | Wu, Lige Zhao, Weiqing Tang, Shuxian Chen, Rui Ji, Mei Yang, Xin |
author_facet | Wu, Lige Zhao, Weiqing Tang, Shuxian Chen, Rui Ji, Mei Yang, Xin |
author_sort | Wu, Lige |
collection | PubMed |
description | Group 2 innate lymphoid cells (ILC2s) are important mediators of type 2 immunity and play an important role in allergic diseases, helminth infections, and tissue fibrosis. However, the role of ILC2s in tumor immunity requires further elucidation. Studies over the past decade have reported that ILC2s play a promoting or suppressing role in different tumors. Here we reviewed the role of ILC2s in solid tumors demonstrating that ILC2s act as a crucial regulator in tumor immunity. We proposed that ILC2s could be an important predictor for tumor prognosis and a new therapeutic target after immunotherapy resistance. In conclusion, our study shed new light on modifying and targeting ILC2s for anti-tumor immunotherapy. |
format | Online Article Text |
id | pubmed-9203687 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92036872022-06-18 Role of ILC2s in Solid Tumors: Facilitate or Inhibit? Wu, Lige Zhao, Weiqing Tang, Shuxian Chen, Rui Ji, Mei Yang, Xin Front Immunol Immunology Group 2 innate lymphoid cells (ILC2s) are important mediators of type 2 immunity and play an important role in allergic diseases, helminth infections, and tissue fibrosis. However, the role of ILC2s in tumor immunity requires further elucidation. Studies over the past decade have reported that ILC2s play a promoting or suppressing role in different tumors. Here we reviewed the role of ILC2s in solid tumors demonstrating that ILC2s act as a crucial regulator in tumor immunity. We proposed that ILC2s could be an important predictor for tumor prognosis and a new therapeutic target after immunotherapy resistance. In conclusion, our study shed new light on modifying and targeting ILC2s for anti-tumor immunotherapy. Frontiers Media S.A. 2022-06-03 /pmc/articles/PMC9203687/ /pubmed/35720302 http://dx.doi.org/10.3389/fimmu.2022.886045 Text en Copyright © 2022 Wu, Zhao, Tang, Chen, Ji and Yang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Wu, Lige Zhao, Weiqing Tang, Shuxian Chen, Rui Ji, Mei Yang, Xin Role of ILC2s in Solid Tumors: Facilitate or Inhibit? |
title | Role of ILC2s in Solid Tumors: Facilitate or Inhibit? |
title_full | Role of ILC2s in Solid Tumors: Facilitate or Inhibit? |
title_fullStr | Role of ILC2s in Solid Tumors: Facilitate or Inhibit? |
title_full_unstemmed | Role of ILC2s in Solid Tumors: Facilitate or Inhibit? |
title_short | Role of ILC2s in Solid Tumors: Facilitate or Inhibit? |
title_sort | role of ilc2s in solid tumors: facilitate or inhibit? |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203687/ https://www.ncbi.nlm.nih.gov/pubmed/35720302 http://dx.doi.org/10.3389/fimmu.2022.886045 |
work_keys_str_mv | AT wulige roleofilc2sinsolidtumorsfacilitateorinhibit AT zhaoweiqing roleofilc2sinsolidtumorsfacilitateorinhibit AT tangshuxian roleofilc2sinsolidtumorsfacilitateorinhibit AT chenrui roleofilc2sinsolidtumorsfacilitateorinhibit AT jimei roleofilc2sinsolidtumorsfacilitateorinhibit AT yangxin roleofilc2sinsolidtumorsfacilitateorinhibit |